Iovance Biotherapeutics Inc
$ 3.78
-2.58%
10 Jun - close price
- Market Cap 1,721,267,000 USD
- Current Price $ 3.78
- High / Low $ 4.06 / 3.76
- Stock P/E N/A
- Book Value 1.65
- EPS -0.92
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.48 %
- 52 Week High 5.63
- 52 Week Low 1.66
About
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.
Analyst Target Price
$8.80
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-31 | 2026-02-24 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -0.19 | -0.18 | -0.25 | -0.33 | -0.36 | -0.26 | -0.28 | -0.34 | -0.42 | -0.45 | -0.46 | -0.47 |
| Estimated EPS | -0.1535 | -0.18 | -0.26 | -0.28 | -0.25 | -0.2676 | -0.3 | -0.35 | -0.42 | -0.43 | -0.46 | -0.79 |
| Surprise | -0.0365 | 0 | 0.01 | -0.05 | -0.11 | 0.0076 | 0.02 | 0.01 | 0 | -0.02 | 0 | 0.32 |
| Surprise Percentage | -23.7785% | 0% | 3.8462% | -17.8571% | -44% | 2.8401% | 6.6667% | 2.8571% | 0% | -4.6512% | 0% | 40.5063% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IOVA
2026-06-11 17:39:26
This article provides the transcript from Iovance Biotherapeutics Inc.'s Annual Shareholders Meeting held on June 10, 2026. The meeting was conducted virtually and included remarks from the Chairman of the Board, Ian Dukes, and attendance by CFO Colleen Roche and Interim CEO Fred Boit. The article contextually lists various past and future earnings calls and conference transcripts for Iovance Biotherapeutics (NAS:IOVA).
2026-06-10 21:09:26
Iovance Biotherapeutics (NASDAQ: IOVA) has received marketing authorization from Australia's Therapeutic Goods Administration (TGA) for its advanced melanoma drug, Amtagvi (lifileucel). This approval marks Amtagvi as the first T cell therapy for solid tumor cancer and the first post-anti-PD-1 option for advanced melanoma in Australia, a country with a high incidence of the disease. Concurrently, Iovance shareholders approved all proposals at their Annual Meeting, including an increase in authorized common stock and an expansion of the Employee Stock Purchase Plan, providing the company with greater financial and equity flexibility.
2026-06-10 14:22:00
Iovance Biotherapeutics (IOVA) has seen significant advancements in its TIL therapy platform with two key developments. The company received conditional approval from Australia's TGA for Amtagvi (lifileucel) to treat advanced melanoma, and the FDA granted allowance for an investigational new drug application for IOV-5001, a next-generation IL-12-tethered TIL therapy. A Phase 1/2 basket trial for IOV-5001 is set to begin in the second half of 2026, targeting various advanced solid tumors.
2026-06-10 00:40:27
Iovance Biotherapeutics' Chief Regulatory Officer, Raj K. Puri, reported routine equity compensation activity involving the vesting of Restricted Stock Units (RSUs) and shares withheld for tax obligations. A total of 9,766 RSUs vested, with 3,843 shares withheld for taxes, not through an open-market sale. Following these transactions, Puri directly holds 251,957 common shares and 68,365 RSUs, with the remaining RSUs scheduled to vest quarterly.
2026-06-09 20:39:57
Frederick G. Vogt, Interim CEO and General Counsel of IOVANCE BIOTHERAPEUTICS (NASDAQ: IOVA), reported the vesting of 15,625 Restricted Stock Units (RSUs) into common stock on June 5, 2026. To cover mandatory tax withholding, 6,638 shares were withheld at $4.23 per share, which was not an open market sale. After these transactions, Vogt directly holds 562,492 shares of common stock and 109,382 RSUs, with the remaining RSUs scheduled to vest in equal quarterly installments.
2026-06-09 20:39:57
Iovance Biotherapeutics' Chief Medical Officer, Friedrich Graf Finckenstein, reported routine equity compensation activity through a Form 4 filing. The report details the vesting of 7,813 restricted stock units (RSUs) and the subsequent withholding of 3,976 common shares for tax purposes. These transactions are part of a compensation plan and do not represent an open market sale.
